Lunai Bioworks (NASDAQ:LNAI) Posts Quarterly Earnings Results

Lunai Bioworks (NASDAQ:LNAI) issued its quarterly earnings results on Tuesday. The company reported ($0.08) EPS for the quarter, Zacks reports.

Lunai Bioworks Trading Up 6.6%

Shares of NASDAQ:LNAI traded up $0.04 during trading on Thursday, reaching $0.62. 87,703 shares of the company traded hands, compared to its average volume of 245,518. The company has a fifty day simple moving average of $0.89. The firm has a market cap of $14.62 million, a price-to-earnings ratio of -8.91 and a beta of 0.46. Lunai Bioworks has a 1-year low of $0.56 and a 1-year high of $14.00.

Institutional Trading of Lunai Bioworks

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC bought a new stake in Lunai Bioworks Inc. (NASDAQ:LNAI) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned about 0.87% of Lunai Bioworks as of its most recent SEC filing. Institutional investors and hedge funds own 71.41% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on LNAI. Wall Street Zen raised shares of Lunai Bioworks from a “sell” rating to a “hold” rating in a research note on Saturday, January 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lunai Bioworks in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Lunai Bioworks has a consensus rating of “Sell”.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.